iOnctura Clinical Trial NewsIOnctura Announces FDA Clearance Of IND Application For Roginolisib, A First-In-Class Allosteric Modulator Of PI3KδThis FDA clearance will allow IOnctura to continue with a clinical trial in the United States.Read more here!READ MOREMegan Bekkedahl2023-12-27T01:35:21+00:00December 27th, 2023|In the press, Latest Publications, Ocular Melanoma, On-going research, Uncategorized|
